Open Access Open Access  Restricted Access Subscription or Fee Access

Self Reported Side Effects of Prophylactic Hydroxychloroquine (HCQ) Usage among Health Care Workers (HCWs) during the Initial Phase of COVID-19 Outbreak

Mini George, Jithin Thomas Parel, Manglam Kumari

Abstract


Background: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. The rising burden of Coronavirus disease (COVID-19) has led to the mass use of hydroxychloroquine by healthcare workers (HCWs). Side effect of this drug when used as prophylaxis is not well known in the literature. Methods: A cross-sectional online survey was carried out using a Google form containing questionnaire on different organ systems. Google forms were shared via Whatsapp. Total 180 subjects participated. Inclusion criteria were the population who had taken Hydrocholoroquine as prophylaxis, and were using Whatsapp. Results: Of the 180 participants, at least 25.6% of participating participants experienced at least one side effect following the use of the drug. Among them, Central Nervous System effects had the maximum incidence with 46 (25.6%) events of side effects. Conclusions: It was premature to recommend HCQ as a panacea for prophylaxis of COVID-19 in absence of robust in vivo and clinical trials. Quarantine, social distancing, vaccination and personal hygiene seems to be the only proven preventative measures in the current scenario.


Full Text:

PDF

References


Zhan M, Qin Y, et al. Death from Covid-19 of 23 health care workers in China. Lancet. 2020; 382(23): 2267-2268.

Savarino A, Boelaert JR, et al. Effects of chloroquine onviral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003; 3(11): 722–7.

Wang M, Cao R, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269–71.

Cortegiani A, Ingoglia G, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; 57: 279–283.

Rathi S, Ish P, et al. Correspondence Hydroxychloroquine. Lancet Infect Dis. 2020; 20(10): 1118-1119.

Ruiz-Irastorza G, Ramos-Casals M, et al. Clinical efficacy and side effects of antimalarials in systemic lupuserythematosus: a systematic review. Ann Rheum Dis. 2010; 69(1): 20–8.

Advisory earlier issued (dated 23rd Mar 2020). Revised advisory on the use of Hydroxychloroquine. [Online] available at: https://www.mohfw.gov.in/pdf/

AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf)

Bruse-Chwatt LJ. Three hundred and fifty years of the Peruvian fever bark. Br Med J (Clin Res Ed). 1988; 296(6635): 1486–7.

FDA. (2020 Jul) FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Plaquenil. [Online] Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or

Yao X, Ye F, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15): 732-739.

Liu J, Cao R, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6(1): 6–9.

Gautret P, Lagier J-C, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1): 105949.

Chen Z, Hu J, et al. Efficacy of hydroxychloroquine inpatients with COVID-19: results of a randomized clinical trial. Med Rxiv. .2020; 7: 20040758.

FDA. Hydroxychloroquine factsheet for healthcare providers. Int J Antimicrob Agents. 2020; 56(1): 105949.

Liu M, Caputi TL, et al. Internet Searches for Unproven COVID-19 Therapies in the United States. J AMA Intern Med. 2020; 180(8): 1116–1118.

Wu C, Liu Y, Yang Y et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5): 766–788.

Wang C, Fortin PR, et al. Discontinuation of antimalarial drugs in systemic lupuserythematosus. J Rheumatol. 1999; 26(4): 808–15.

Costedoat-Chalumeau N, Hulot JS, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology. 2007; 46(5): 808–10.

Wozniacka A, Cygankiewicz I, et al. The cardiac safety of chloroquine phosphate treatment in patients with systemic lupuserythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters. Lupus. 2006; 15(8): 521–5.

Abubakar AR, Simbak N, et al. A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors. J Appl Pharm Sci. 2014; 4(10): 117–27.

ClinicalTrials.gov. (2020 Dec) Will Hydroxychloroquine Impede or Prevent COVID-19. [Online] Available from https://clinicaltrials.gov/ct2/show/NCT04341441

ClinicalTrials.gov. (2020 Dec). The PATCH Trial (Prevention and Treatment of COVID-19 with Hydroxychloroquine). [Online] Available form https://clinicaltrials.gov/ct2/show/NCT04329923

ClinicalTrials.gov. (2020 Oct). Safety and Efficacy of Hydroxychloroquine for at Risk Population (SHARP) against COVID. [Online] Available from: https://clinicaltrials.gov/ct2/show/NCT04342156

Rayhan RU, Zheng Y, et al. Administer and collect medical questionnaires with Google documents: a simple, safe, and free system. Appl Med Informatics. 2013; 33(3): 12–21.

Van Gelder MMHJ, Bretveld RW, et al. Web-based questionnaires: the future in epidemiology? Am J Epidemiol. 2010; 172(11): 1292–8.

Parel JT, Varshney M, et al. Feeling the Early Impact of COVID-19 Pandemic: Mental Health of Nurses in India. J Depress Anxiety. 2020; 9(5): 381.

Varshney M, Parel JT, et al. Initial psychological impact of COVID-19 and its correlates in Indian Community: An online (FEEL-COVID) survey. PLoS ONE. 2020; 15(5): e0233874.




DOI: https://doi.org/10.37628/ijmsn.v4i2.1910

Refbacks

  • There are currently no refbacks.